PF-Atlas › Clinical Trials › NCT02734810
SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
Liprotamase Powder for Oral Solution · Phase 3
Registry ID
NCT02734810
Phase
Phase 3
Status
Completed
Drug / intervention
Liprotamase Powder for Oral Solution
Sponsor
Anthera Pharmaceuticals
Start
2016-06
About this trial
Liprotamase Powder for Oral Solution is evaluated in NCT02734810, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Anthera Pharmaceuticals. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02734810 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.